SLMP53-1 is a novel reactivator of wild-type and mutant p53, shows a p53-dependent anti-proliferative activity in human wt and mut p53R280K-expressing tumor cells.

TRIF agonist AV-C is a novel TRIF pathway agonist that activates innate and interferon-associated responses, strongly inhibits replication of ZIKV, CHIKV, and DENV (IC90~5 uM).

Se-Methylselenocysteine, a precursor of Methylselenol, has potent cancer chemopreventive activity and anti-oxidant activity. Se-Methylselenocysteine is orally bioavailable, and induces apoptosis.

A potent, specific, competitive inhibitor of choline kinase-α (Chok-α) by targeting the choline binding site; significantly increases LC3II expression in MCF-7 and MCF-7/TAM cells, increases the size and number of autophagosome, causes MCF-7 and MCF-7/TAM

PF 04878691 (PF 4878691, S 32865, 852A, 3M 001) is a selective TLR7 agonist that potently induces IFN-α and IFN-regulated proteins from human PBMC.

BK-1361(BK1361, cyclo-RLsKDK) is a cyclic peptide with RLsKDK (s=D-serine) that functions as a potent, selective inhibitor of ADAM8 with IC50 of 120 nM.

GPR4 antagonist 3 is a selective, and orally available GPR4 antagonist with an IC50 of 70 nM. Anti-inflammatory activities.

LLY-283 (LLY283) is a potent, selective inhibitor of arginine methyltransferase 5 (PRMT5) with IC50 of 22 nM.

S-99 inhibits LPS-induced TNFa release assay in vivo

RO495 is a very potent TYK2 inhibitor with a IC50 of 1.5nM on TYK2 as tested in cell-based pharmacological assays

NIBR-17 is a pan class I PI3K inhibitor with IC50 values of 1, 9.2, 9 and 20 nM respectively for PI3Kapha - delta.

GNE-490 is a highly selective pan-PI3K inhibitor and demonstrates selectivity over mTOR.

GDC046 is a potent lead analog with good kinase selectivity, physicochemical properties, and pharmacokinetic profile.

AMG-1 is a potent inhibitor of human c-Met and RON with IC50 values of 4 and 9 nmol/L respectively.

The compound (Akt-I-1) inhibits only Akt1 (IC50 4.6 μM) and does not inhibit AKT2, or AKT3.

Rogaratinib (BAY 1163877) is a potent, selective, orally available pan-FGFR with IC50 of 15, <1, 19 and 33 nM for FGFR1, 2, 3 and 4, respectively.

NVP-2 is a potent and selective ATP-competitive cyclin dependent kinase 9 (CDK9) probe, inhibits CDK9/CycT activity with an IC50 of 0.514 nM. NVP-2 displays inhibitory effcts on CDK1/CycB, CDK2/CycA and CDK16/CycY kinases with IC50 values of 0.584 µM, 0.7

Purfalcamine is a potent, specific inhibitor of Plaasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) with IC50 of 17 nM.

MN58b is a potent, selective choline kinase α (ChoKα) inhibitor with IC50 of 1.4 uM, >30-fold selectivity over ChoKβ and does not affect MAPKs, PI3Ks, and other enzymes involved in the regulation of phospholipid metabolism.

ML188 is a Potent Noncovalent Small Molecule Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL Protease. The X-ray structure of SARS-CoV 3CLpro bound with ML188 was instrumental in guiding subsequent rounds of chemistry optimiz

MK2-IN-1 is a potent, selecitve, non-ATP competitive MAPKAPK2(MK2) inhibitor with IC50 of 0.11 uM.

LY-345899 (LY345899) is a novel potent, cytoplasmic and mitochondrial methylenetetrahydrofolate dehydrogenase MTHFD1 and MTHFD2 inhibitor with IC50 of 96 nM and 663 nM, respectively; MTHFD2 is a novel target for drug development.

Goserelin is a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. Goserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Prolonged administration of goserelin inh

Plecanatide acetate is a guanylate cyclase-C (GC-C) receptor agonist, binds and activates GC-C receptor, with an EC50 of 190 nM in T84 cells. Plecanatide acetate shows an-inflammatory activity in models of murine colitis.

BI01383298 (BI-01383298) is a potent, specific sodium-citrate co-transporter SLC13A5 (NaCT, INDY), highly selective over other family members and other transporters..

Risdiplam (RG7916, RG-7916, RO7034067) is a highly potent, selective, orally active SMN2 splicing modifier for treatment of spinal muscular atrophy (SMA).

TAK-659 (TAK659, Mivavotinib) is a potent, selective and orally available SYK inhibitor with IC50 of 3.2 nM.

LIN28 inhibitor LI71 is a potent, cell-permeable inhibitor of LIN28 that abolishes LIN28-mediated oligouridylation with IC50 of 7 uM, binds the cold shock domain to suppress LIN28's activity against let-7 in leukemia cells and embryonic stem cells. .

A novel potent, selective CDK8 inhibitor with IC50 of 0.5 uM against recombinant Cyclin C/CDK8 complex.

SEL-201 (SLV-2436, SEL201-88) is a novel potent, selective, ATP-competitive and oral MNK1/2 inhibitor with IC5010.8/5.4 nM, respectively.